This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (14)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Bacterial Infections  • Tuberculosis/ Other Mycobacterium  • Alert me on articles by topic

The Genie Is out of the Bottle

C. Robert Horsburgh, Jr, MD, MUS

JAMA. 2000;283:2575-2576.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Drug-resistant tuberculosis (TB) was first observed in 1948, subsequent to the first trials of streptomycin for TB treatment.¹ Ever since then, drug-resistant TB has been recognized to occur as the result of suboptimal TB treatment. In a recent survey of 35 countries, 12.6% of Mycobacterium tuberculosis isolates were resistant to at least 1 drug, and 2.2% were resistant to both of the primary drugs used to treat TB, isoniazid and rifampin.² Thus, today most cases of TB are drug susceptible at the time of diagnosis, only becoming drug resistant through suboptimal therapy. Therefore, the World Health Organization has focused its efforts to combat multidrug-resistant TB on a strategy of preventing the generation of new multidrug-resistant TB cases. This program, directly observed therapy short-course (DOTS), relies on local government commitment to a sustained effort using case detection by sputum microscopy, directly observed treatment with a . . . [Full Text of this Article]

Author Affiliation: Schools of Public Health and Medicine, Boston University, Boston, Mass.

RELATED ARTICLE

Standard Short-Course Chemotherapy for Drug-Resistant Tuberculosis: Treatment Outcomes in 6 Countries
Marcos A. Espinal, Sang Jae Kim, Pedro G. Suarez, Kai Man Kam, Alexander G. Khomenko, Giovanni B. Migliori, Janette Baéz, Arata Kochi, Christopher Dye, and Mario C. Raviglione
JAMA. 2000;283(19):2537-2545.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis
Condos et al.
Chest 2008;134:187-192.
ABSTRACT | FULL TEXT  

Cost-effectiveness of isoniazid chemoprevention in close contacts
Diel et al.
Eur Respir J 2005;26:465-473.
ABSTRACT | FULL TEXT  

Reduced up-regulation of memory and adhesion/integrin molecules in susceptible mice and poor expression of immunity to pulmonary tuberculosis
Gruppo et al.
Microbiology 2002;148:2959-2966.
ABSTRACT | FULL TEXT  

India's Multidrug-Resistant Tuberculosis Crisis
UDWADIA
Ann. N. Y. Acad. Sci. 2001;953:98-105.
ABSTRACT | FULL TEXT  

Antiretroviral Agents Restore Mycobacterium-Specific T-Cell Immune Responses and Facilitate Controlling a Fatal Tuberculosis-Like Disease in Macaques Coinfected with Simian Immunodeficiency Virus and Mycobacterium bovis BCG
Shen et al.
J. Virol. 2001;75:8690-8696.
ABSTRACT | FULL TEXT